An elderly woman with no known cardiovascular issues is seen for acute onset palpitations, dyspnea, and chest pain.
Editor's Choice PCARDIO
What drug has shown survival benefit greater than 3 months in high-risk PAH patients? Select your answer and move to the next question.
The practice of CVD risk estimation shifted radically in 2013. The ACC-AHA app helps you connect the new dots.
ORLANDO -- Barely half of patients with atrial fibrillation who were prescribed rivaroxaban (Xarelto) to prevent stroke remained on the treatment after 2 years, but their adherence was still better than Afib patients on warfarin or dabigatran (Pradaxa), researchers said here.
A 35-year-old man presents to the emergency department complaining of syncope. He denies any preceding chest pain, palpitations or trouble breathing, and states he did not injure himself other than a bump on his forehead.
Men with documented testosterone deficiency should be allowed to take testosterone replacement therapy if they have cardiovascular disease (CVD) or localized prostate cancer, according to new guidelines issued by the Canadian Men’s Health Foundation.
One of the biggest advances in the world of nonvalvular atrial fibrillation was the introduction of the novel oral anticoagulants (NOACs) for decreasing thromboembolic risk.
Congestive heart failure (with decreased ejection fraction) has always been recognized as a risk factor for stroke or systemic embolism in patients with atrial fibrillation (AF) and is included in the CHA2DS-VASc risk score calculation.